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Community-acquired methicillin-resistant Staphylococ-
cus aureus (CA-MRSA) infections are common in south-
western Alaska. Outbreak strains have been shown to carry 
the genes for Panton-Valentine leukocidin (PVL). To deter-
mine if carriage of PVL-positive CA-MRSA increased the 
risk for subsequent soft tissue infection, we conducted a ret-
rospective cohort study by reviewing the medical records of 
316 persons for 3.6 years after their participation in a MRSA 
nasal colonization survey. Demographic, nasal carriage, 
and antimicrobial drug use data were analyzed for associa-
tion with skin infection risk. Skin infections were more likely 
to develop in MRSA carriers than in methicillin-susceptible 
S. aureus carriers or noncarriers of S. aureus during the 
ﬁ  rst follow-up year, but not in subsequent years. Repeated 
skin infections were more common among MRSA carriers. 
In an area where PVL-containing MRSA is prevalent, skin 
infection risk was increased among MRSA nasal carriers 
compared with methicillin-susceptible S.aureus carriers and 
noncarriers, but risk differential diminished over time. 
M
ethicillin-resistant Staphylococcus aureus (MRSA) 
has become a primary cause of skin and soft tissue 
infections among persons without extensive exposure to 
healthcare settings. Nasal carriage of S. aureus is a known 
risk factor for these infections (1–3) and a common reser-
voir during skin and soft tissue infection outbreaks (4–6). 
Such outbreaks have occurred in community (7–10) set-
tings, e.g., athletic team facilities (11–16), correctional fa-
cilities (13,17), and military basic training camps (18,19). 
Risk factors found in these community settings are frequent 
skin-to-skin contact (11,12,14,15), sharing of personal 
items without frequent cleaning (11–14), and MRSA car-
riage (18,20). Nasal colonization is also a risk factor for 
infections in hospital settings (4–6,21–23) and long-term 
care facilities (24,25). However, all of these previous stud-
ies have used a case–control study design, making it impos-
sible to determine if MRSA carriage preceded infection.
Little is known about the subsequent risk for skin 
and soft tissue infections among persons colonized with 
MRSA. This lack of information becomes a question of 
clinical signiﬁ  cance because increasing numbers of MRSA 
case-cluster investigations include nasal colonization stud-
ies that identify persons as MRSA-colonized. Clinicians 
and patients are left to consider whether interventions such 
as decolonization, continued monitoring, or restrictions in 
occupational activities are indicated. The notable absence 
of data regarding subsequent risk for illness among MRSA-
colonized persons in community settings does little to in-
form these treatment decisions.
In southwestern Alaska, a dramatic increase in the num-
ber of skin infections led to an investigation by the Centers 
for Disease Control and Prevention and the Yukon Kuskok-
wim Health Corporation in 2000. MRSA exhibiting the type 
IV staphylococcal cassette chromosome mec gene had be-
come the predominant community strain in that region, ac-
counting for 100% of S. aureus isolates from skin infections 
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(7,8). Also, the USA400 strain is the predominant strain of 
CA-MRSA in this area, whereas USA300 is the predomi-
nant strain in most other areas of the United States (8). In 
that initial investigation, we conducted a case–control study 
in 1 village in Alaska to assess risk factors for MRSA skin 
infections and evaluated nasal carriage among case–control 
participants and their household members (1). The present 
study is a follow-up assessment of participants in the prior 
nasal colonization survey. Our goal was to assess the risk 
for subsequent skin infections among persons whose nares 
cultures were colonized with MRSA (carriers) compared 
with those colonized with methicillin-susceptible S. aureus 
(MSSA), or those whose nares cultures were negative for S. 
aureus (non–S. aureus carriers).
Methods
This retrospective cohort study included persons who 
had been enrolled in a case–control study conducted in Sep-
tember 2000, which included anterior nares swab cultures 
for S. aureus obtained by using standard methods (1). The 
316 study participants included 32 persons with a history 
of a culture-conﬁ  rmed S. aureus skin infection (furuncu-
losis or cellulitis) in the data collection period, 90 persons 
with no skin infection history in the year before the case–
control study, and 194 household members of case- and 
control-patients. All persons were residents of 1 southwest 
Alaska village (population 713, accessible only by river or 
airplane) (26). Healthcare is provided by 1 integrated sys-
tem, which includes a primary care clinic in the village and 
1 regional hospital. The study was approved by the Insti-
tutional Review Board of the Centers for Disease Control 
and Prevention, area review boards in Alaska, and the local 
tribal health authority. A waiver of informed consent was 
obtained that enabled use of data from existing sources af-
ter delinking from individual identiﬁ  ers.
Data Collection
We reviewed the medical records of all 316 persons 
to determine the total clinic or hospital visits by patients 
with skin infections or those for which an antimicrobial 
drug was prescribed during September 20, 2000–May 2, 
2004 (3.6 years). Each participant’s age, sex, S. aureus car-
riage status at the beginning of the study, and whether he 
or she lived with a MRSA carrier were recorded. We de-
ﬁ  ned an antimicrobial drug course as a prescription for any 
oral or parenteral antimicrobial agent. Prescriptions involv-
ing simultaneous administration of >1 antimicrobial drug 
were counted as 1 course, as were changes in antimicrobial 
treatments for the same illness course that may have re-
sulted from a participant’s inadequate response to empiric 
therapy. For continuous prophylactic antimicrobial drugs, 
each month was counted as 1 course of treatment. Topical 
antimicrobial drugs were not counted.
Skin infections were deﬁ  ned as furuncles/abscesses, 
cellulitis, folliculitis, or deep wound infections as docu-
mented by the clinical provider. For each patient, we re-
corded visit date, diagnosis, anatomic site of infection, 
pathogen (if available), and consequent antimicrobial drug 
therapy. Visits for impetigo, scabies, and dermatitis were 
not included in the analysis. We considered skin infections 
to be distinct episodes if they occurred in the same ana-
tomic site >6 months apart, and in different anatomic sites 
if they occurred >2 months apart. Only the ﬁ  rst visit for 
treatment of a skin infection episode was recorded if there 
were multiple visits for the same episode. Nasal coloniza-
tion was assessed only at the onset of the study. Isolates 
from skin infections of study participants were not avail-
able for comparison with nasal colonization specimens.
Statistical Analysis
Univariate analyses were performed to compare de-
mographic and clinical characteristics among 3 carriage 
groups (MRSA, MSSA, and non–S. aureus infections). De-
mographic characteristics included age, sex, and S. aureus 
colonization status of household members. Clinical char-
acteristics included the type and anatomic site of the skin 
infection, identiﬁ  ed pathogens, and current history of anti-
microbial drug treatment. Analyses were performed by us-
ing SAS version 8 software (SAS Institute, Inc., Cary, NC, 
USA). Univariate comparisons of categorical and continu-
ous variables were conducted by using the χ2 and Kruskal-
Wallis tests, respectively. We assessed confounding of 
demographic characteristics through use of the Cochran-
Mantel-Haenszel test. The Kaplan-Meier method was used 
to determine risk for ﬁ  rst skin infection over time for each 
of the 3 groups. The log-rank statistic was used to compare 
survival (time without a skin infection) between carriage 
groups. Persons were censored at the time of death (n = 5) 
or at the time of last contact with the healthcare system for 
those who were known to have moved from the village (n 
= 3). We assessed confounding of other variables with a 
stratiﬁ  ed nonparametric survival test (27).
Results
Study Population
Of the 316 participants, 41 (13%) were colonized with 
MRSA at the beginning of the study period (September 20, 
2000); 85 (26.9%) were colonized with MSSA, and 190 
(60.1%) were not colonized with S. aureus. Nasal carriage 
ﬁ  ndings are described in more detail in a report of the prior 
case–control study (1). For the purposes of this study, 10 
(24.4%) of those colonized with MRSA had been included 
as case-patients with a history of skin infections in the prior 
case–control study, 3 (7.3%) were control-patients with 
no history of skin infections in the previous year, and 28 
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(68.3%) were household members of case- or control-pa-
tients whose skin infection history before the study period 
was not obtained. Of those colonized with MSSA, 2 partici-
pants were case-patients, 28 were control-patients, and 55 
were household members. Of the noncarriers, 20 were case-
patients, 59 were control-patients, and 111 were household 
member participants. MRSA carriers were more likely to 
have a household member who was also a MRSA carrier 
(78%) compared with MSSA carriers (29%) and non–S. 
aureus carriers (17%) (p<0.0001). S. aureus carriers were, 
on average, younger (median 14 years) than non–S. aureus 
carriers (median 22 years, p = 0.02) (Table 1). However, 
MRSA carriers (median 13 years) and MSSA carriers (me-
dian 16 years) were of similar ages (p = 0.46).
Risk for Skin Infection
During the ﬁ  rst year after the carriage study, >1 skin 
infections developed in 107 (33.9%) participants. Skin 
infections were more likely to develop in MRSA carri-
ers (23/41 [56.1%]) compared with MSSA carriers (27/85 
[31.8%], relative risk [RR] 1.76) and non–S. aureus carriers 
(57/190 [30.0%], RR 1.87, p = 0.005). For persons who did 
not have a skin infection diagnosed in the ﬁ  rst year, the risk 
for developing a skin infection in the 2 to 3.6-year period 
did not differ signiﬁ  cantly by carrier status: 5/18 (27.8%) 
of MRSA carriers, 20/58 (34.5%) of MSSA carriers, and 
59/133 (44.4%) of noncarriers (p = 0.23). Over the entire 
3.6-year follow-up period, >1 skin infections developed 
in a higher proportion of MRSA carriers (28/41 [68.3%]) 
than in MSSA carriers (47/85 [55.3%]) and non–S. aureus 
carriers (116/190 [61.1%]), but these differences were not 
statistically signiﬁ  cant (p = 0.36). Rates for skin infections 
for the ﬁ  rst 3 years of follow-up are shown in Table 2.
The median age of persons in which skin infections 
developed in the ﬁ  rst year was 17 years and was similar for 
each carriage group (p = 0.50). Among persons in which 
skin infections developed during the full study period, the 
median age was similar for MRSA carriers (median 16.5 
years) and MSSA carriers (median 14 years, p = 0.7), but 
was higher for non–S. aureus carriers (median 22 years, p 
= 0.06 vs. MRSA carriers).
The number of skin infections in the ﬁ  rst year was 
higher for MRSA carriers (mean 0.7) than for either MSSA 
carriers (mean 0.4) or non–S. aureus carriers (mean 0.4, 
Table 2). For the entire follow-up period, MRSA carriers 
had a mean of 1.9 skin infections per person, which ex-
ceeded that of MSSA carriers (mean 1.2, p = 0.04) and the 
non–S. aureus carriers (mean 1.1, p = 0.02). No difference 
was detected in the numbers of skin infections by sex and 
carriage group in either analysis of the ﬁ  rst year (p>0.3) or 
the full study period (p>0.9).
Among MRSA-colonized persons, skin infection risk 
did not differ by the colonization status of household mem-
bers (p>0.22). However, among non–MRSA-colonized 
persons, skin infection risk in the ﬁ  rst year was higher for 
those with a MRSA–colonized household member (23/57 
[40%]) compared with those without a MRSA−colonized 
household member (61/208 [24%], RR 1.4, 95% conﬁ  -
dence interval [CI] 1.0–2.1, p = 0.007); this difference did 
not persist when considering the entire follow-up period (p 
= 0.4). After adjusting for household member MRSA colo-
nization, the RR for developing a skin infection in the ﬁ  rst 
year was 1.6 (95% CI 1.1–2.4) when comparing MRSA 
carriers versus non–S. aureus carriers.
By using survival analysis, we found that after 1 year 
MRSA carriers were more likely than non–S. aureus carri-
ers to have had a skin infection (RR 1.9, 95% CI 1.3–2.6, 
p = 0.001; Table 2). After 1 year, no difference was de-
tected in the occurrence of a ﬁ  rst skin infection between 
MSSA carriers and non–S. aureus carriers (p = 0.69). After 
2 years, an increased risk remained between MRSA and 
non–S. aureus carriers (p = 0.02), but after 3 years this dif-
ference was no longer signiﬁ  cant (Table 2). We stratiﬁ  ed 
by gender, age, and household member colonization status; 
the results remained unchanged. The estimated length of 
time for 50% of the MRSA carriage group to have devel-
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Table 1. Characterization of study participants by Staphylococcus aureus carriage group, Alaska, 2000* 
Characteristic 
MRSA carriers, 
n = 41 
MSSA carriers, 
n = 85 
Non–S. aureus 
carriers, n = 190  Total, n = 316  p value†
 
Male sex  23 (56.1)  40 (47.1)  94 (49.5)  157 (49.7)  0.6 
Median age, y (range)  13 (0–77)  16 (1–73)  22 (0–85)  18 (0–85)   
Age group, y           
 <5  10 (24.4)  17 (20.0)  29 (15.3)  56 (17.7)  0.0456 
 5–19  15 (36.6)  35 (41.2)  57 (30.0)  107 (33.9)   
 20–39  9 (22.0)  20 (23.5)  60 (31.6)  89 (28.2)   
 40–64  6 (14.6)  9 (10.6)  32 (16.8)  47 (14.9)   
 >64  1 (2.4)  4 (4.7)  12 (6.3)  17 (5.4)   
Household member nasal carriage status          
 > 1 MRSA+  32 (78.0)  25 (29.4)  32 (16.8)  89 (28.2)  <0.0001 
*Values are no. (%) except as indicated. MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus.  
†Ȥ
2 tests were used to detect differences in carriage groups by sex and household member status; nonparametric 1-way analysis of variance software 
(SAS Institute, Cary, NC, USA) was used to detect differences in carriage groups by age. RESEARCH
oped a skin infection was 289 days (0.8 years), 1,049 days 
(2.9 years) for MSSA carriers, and 804 days (2.2 years) for 
non–S. aureus carriers (Figure).
Skin Infection Characterization
A total of 391 skin infections occurred during the 
3.6-year follow-up. Of these, 246 (62.9%) presented as 
a single furuncle; 85 (21.7%) were multiple furuncles; 50 
(12.8%) had evidence of cellulitis; 4 (1.0%) were diag-
nosed as folliculitis; and 6 (1.5%) were deep abscesses. 
One hundred thirteen (45.9%) single boils occurred in the 
buttocks/low back/thigh area; 35 (41.2%) multiple boil 
infections occurred on the buttocks/low back/thigh area. 
Thirty-three (66.0%) of the cellulitis infections occurred 
on the extremities.
For all skin infections on which antimicrobial drug 
data were available, 264 of 382 (69.1%) patients were pre-
scribed antimicrobial drugs. We found no difference in the 
mean number of antimicrobial drug treatment prescribed 
over the study period to S. aureus carriers compared with 
non–S. aureus carriers (12.0 vs. 10.4, respectively; p = 
0.12) or for MRSA carriers (mean 13.6) as compared with 
MSSA carriers (mean 11.3, p = 0.17).
During the entire course of follow-up, 79/383 (21%) of 
infections (7 with an unknown culture status) were cultured. 
The proportion of skin infections cultured was similar for 
MRSA carriers (22%), MSSA carriers (22%), and non–S. 
aureus carriers (20%). In the 3.6 year follow-up period, 70 
(89%) skin infections cultured were MRSA, 6 (8%) were 
MSSA, and 3 (4%) were other pathogens. Over the entire 
study period, 12/41 (29%) of MRSA carriers had a MRSA 
conﬁ  rmed skin infection, compared with 12/85 (14%) of 
MSSA carriers and 30/190 (16%) of non–S. aureus carri-
ers (p = 0.05 for MRSA vs. MSSA carriers, p = 0.004 for 
MRSA vs. non–S. aureus carriers, and p = 0.72 for MSSA 
vs. non–S. aureus carriers).
Discussion
In this study of a rural village in southwestern Alaska 
where MRSA was responsible for 86% of skin infections, 
we recruited a cohort of participants from a community set-
ting to determine risk factors for the development of skin 
infections. We found nasal MRSA carriage to be a signiﬁ  -
cant risk factor for skin infections in the ﬁ  rst year when 
compared with MSSA and non–S. aureus carriers. More 
skin infection episodes also developed in these MRSA car-
riers than other carriage groups in the ﬁ  rst year and entire 
3.6-year follow-up period. We note that the risk for skin 
infections among MRSA carriers decreased with time but 
not for MSSA or non–S. aureus carriers; rates did not dif-
fer signiﬁ  cantly between the 3 groups by the end of the 
study period. MRSA was the cause of 90% of skin infec-
tions in the follow-up period, with a similar proportion of 
cultures obtained among the carriage groups. Notably, skin 
infection took longer to develop in MSSA carriers, which 
may suggest that MSSA carriage provides some protec-
tion against MRSA infection. The strengths of this study 
are the long follow-up period, the single healthcare system 
that enabled capture of all clinic and hospital visits, and the 
location (an isolated community, which had recently expe-
rienced an outbreak of MRSA skin infections).
Having a household member who was a MRSA car-
rier was associated with an increased risk for skin infection 
in the ﬁ  rst follow-up year for MSSA carriers and non–S. 
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Table 2. Staphylococcus aureus skin infections among study participants, by year, Alaska, 2000–2004* 
Skin infection outcome 
MRSA carriers, 
n = 41 
MSSA carriers, 
n = 85 
Non–S. aureus
carriers, n = 190 
p value 
MRSA vs.
non–S. aureus
MSSA vs.  
non–S. aureus
Skin infection rate, %
 Year  1  56 32 30 0.001  0.77
 Year  2  37 26 30 0.42 0.50
 Year  3  32 21 21 0.15 0.98
Cumulative % with >1 skin infection† 
 Year  1  56 32 30 0.001  0.69
 Year  2  61 41 48 0.02 0.48
 Year  3  66 52 58 0.07 0.50
1st year of follow-up 
  Mean no.  skin infections‡ 0.7 0.4 0.4 0.001  0.73
  No. (%) with >2 infections§ 6 (15)  7 (8)  13 (7)  0.10 0.68
Entire follow-up period, 3.6 y 
  Mean no. skin infections‡ 1.9 1.2 1.1 0.03 0.60
  No. (%)  with >3 infections§ 13 (32)  13 (15)  24 (13)  0.02 0.72
*MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus. Skin infection rate per 100 persons in each of the 3 years; 
2-sample Poisson test was used to compare skin infection rates. 
†Comparisons made by use of Log-Rank statistic in Kaplan-Meier estimation of survival curve. 
‡Comparisons made by use of Kruskal-Wallis statistic. 
§Chi-square test used for calculation of p value. MRSA and Skin Infections, Alaska
aureus carriers but not for MRSA carriers. Studies by Bou-
baker et al. (28) and Osterlund et al. (9) have shown that 
household members of MRSA–colonized persons are at 
increased risk for becoming colonized. Our data support 
the hypothesis that transmission of MRSA from carriers to 
non-colonized household members is a risk factor for dis-
ease acquisition. Transmission of MRSA from household 
carriers during the follow-up period may also explain the 
continued risk for skin infections observed among MSSA 
and non–S. aureus carriers throughout the study. In con-
trast, the risk for skin infection among MRSA carriers was 
greatest in the ﬁ  rst follow-up year but decreased thereafter, 
possibly indicating acquisition of immunity in this group. 
It is crucial to note that after the initial assessment the nasal 
carriage status of participants is unknown.
In the case–control study that preceded this investiga-
tion, antimicrobial drug use in the 12 months preceding the 
MRSA outbreak was associated with an increased risk for 
MRSA infection (1). However, in this study antimicrobial 
drug use did not differ among the 3 carriage groups and thus 
was not associated with subsequent risk for disease from 
MRSA. The small sample size of cultured skin infections 
and changes in clinical guidelines limit detection of any as-
sociation. Antimicrobial drug use may still be a risk factor 
for MRSA infection in this community, although it was not 
demonstrated in this cohort. Alternatively, this ﬁ  nding may 
indicate a decreased role for antimicrobial drugs as a risk 
factor for MRSA infection once MRSA is established as a 
common colonizing organism in a community.
Our study population experienced a high incidence 
of skin infections compared with those in other published 
reports. In the ﬁ  rst follow-up year, we found that 56% of 
MRSA carriers, 32% of MSSA carriers, and 30% of non–S. 
aureus carriers developed skin infections. A similar study 
by Muder et al. in a long-term care facility showed infec-
tion rates of 25%, 4%, and 4% for the same carriage groups, 
respectively, but patients were only followed while in the 
hospital and median duration of follow-up was <1 year 
for the carriage groups (24). Another prospective study of 
soldiers by Ellis et al. found that 38% of MRSA carriers, 
3% of MSSA carriers, and 2% of non–S. aureus carriers 
developed subsequent skin infections (18). The higher inci-
dence of skin infections may have been due, in part, to the 
absence of piped in-home water and wastewater service in 
this village. Lack of in-home running water has been as-
sociated with increased rates of skin and respiratory tract 
infections in rural Alaska, presumably due to decreased op-
portunities for hand and body hygiene. When household 
water must be carried into the home in buckets, residents 
may not wash their hands or bathe as often as they would 
if they had water available by turning a tap (29). The high 
skin infection rates could also be due to MRSA-colonized 
bioﬁ  lms in saunas; 49% of saunas tested were positive for 
outbreak-strain MRSA. Sauna use >2 hours per week was 
reported by 68% of participants (1).
This study had several limitations. Persons with a his-
tory of frequent skin infections before the follow-up period 
may have been more likely to develop skin infections dur-
ing the chart review period. However, we were not able to 
control for the potential confounder of past skin infections 
because of the limited dataset available on the cohort. Se-
lective pressure for CA-MRSA carriage may have dimin-
ished during the follow-up period, because new antimicro-
bial drug treatment guidelines were implemented to reduce 
overtreatment with broad-spectrum antimicrobial drugs and 
ﬁ  rst-generation cephalosporins as the outbreak progressed. 
Another limitation is that S. aureus nasal carriage status was 
assigned based on cultures performed at the beginning of 
the study period but colonization status was not assessed 
further; nasal carriage of S. aureus is known to be naturally 
transient in many carriers, or may also have been affected by 
use of antimicrobial drugs. Therefore, the effect of duration 
of carriage or crossover from 1 study group to another could 
not be determined. Study participants could have moved or 
been lost to follow-up, therefore these data represent mini-
mal incidence estimates for the population. Another limita-
tion is that behavioral data were not available for known 
risk factors for MRSA skin infections, such as sauna use or 
skin contact. MRSA carriage can occur in other body sites, 
such as the groin or axillae; our nasal carriage survey may 
have underestimated actual MRSA carriage.
Our study supports the hypothesis that nasal carriage 
of MRSA is a risk factor for skin infections, and that the 
risk may decrease over time relative to MSSA carriers and 
non–S. aureus carriers. We found that MRSA carriage 
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Figure. Kaplan-Meier survival curve of time until ﬁ  rst skin infection 
among methicillin-resistant Staphylococcus aureus (MRSA), 
methicillin-susceptible  S. aureus (MSSA), and non–S. aureus 
carriers (NC). Black dots and associated text show the median time 
to ﬁ  rst skin infection for each of the 3 groups.RESEARCH
among household members increased the risk for skin infec-
tion among non–MRSA carriers. This information may be 
useful for education of persons identiﬁ  ed as MRSA carriers 
or with MRSA–colonized household members to reinforce 
the value of hand hygiene practices and other measures that 
have been recommended to prevent the spread of MRSA 
within households. Further study of MRSA transmission in 
community settings is needed along with interventions that 
are designed to minimize pathogen transmission to close 
contacts and household members. 
Ms Stevens is a fourth-year medical student at the University 
of Washington School of Medicine in Seattle. Her research inter-
ests include infectious diseases in rural underserved and interna-
tional populations.
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